H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Oncternal Therapeutics to $28 from $30 and keeps a Buy rating on the shares following the Q4 report. The firm dropped the target after taking higher operating expenses in the future into account.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCT:
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
- Oncternal Therapeutics files $250M mixed securities shelf
- Oncternal Therapeutics reports Q4 EPS ($3.11), consensus (3.07)
- Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Oncternal Therapeutics (ONCT) Q4 Earnings Cheat Sheet
